Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Tenax Therapeutics (TENX) Stock Price & Analysis

738 Followers

TENX Stock Chart & Stats

$1.63-$0.18(-9.94%)
At close: 4:00 PM EST
$5$10Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$1.57 - $1.77
52-Week Range
$1.31 - $19.40
Previous Close
$1.81
Volume
N/A
Average Volume (3M)
2.09M
Market Cap
$67.74M
Enterprise Value
$622.17M
Total Cash (Recent Filing)
$113.73M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.58
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
-0.36
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Debt Balance Sheet

Essentially no debt reduces interest obligations and gives Tenax greater financial flexibility while its clinical programs advance. The balance-sheet position can provide a cushion against operating volatility, although continued losses mean that funding needs still require disciplined capital management.

Clinical Biomarker Signals

The reported biomarker and cardiac-function improvements support the biological rationale for levosimendan in a difficult cardiopulmonary disease segment. If replicated in a better-targeted population, these signals could strengthen the product profile and support future regulatory discussions.

Refined Patient Targeting

Using trial data to focus enrollment on patients with greater baseline functional limitation reflects an adaptive, data-driven development strategy. Better patient selection could improve the likelihood of detecting treatment benefit and make the remaining Phase 3 program more informative.

Bears Say

Pre-Revenue Business Model

Tenax has no recurring product revenue to offset research and development spending, leaving its financial profile dependent on external funding or future strategic transactions. Until a candidate reaches commercialization or another durable inflow emerges, operating progress remains disconnected from revenue generation.

Accelerating Cash Burn

The sharp deterioration in free cash flow indicates that the cost of advancing the pipeline is rising faster than internal cash generation. Persistent and accelerating burn can shorten funding runway, increase reliance on financing, and constrain the company’s ability to sustain development without additional capital.

Phase 3 Execution Setback

Failure to meet the overall primary endpoint weakens confidence in the current evidence base and makes the next registrational readout more dependent on revised trial design. Pausing enrollment also adds execution complexity and can extend the path toward a definitive regulatory outcome.

Tenax Therapeutics News

TENX FAQ

What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $1.31 and its highest was $19.40 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $67.74M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 146 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Nov 05, 2026. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.358 by $0.048.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 37,423,916 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.358. Following the earnings report the stock price went down -9.945%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Hedge funds hold Tenax Therapeutics shares: the largest hedge-fund position in Tenax Therapeutics is 71,886,792 shares, and hedge funds increased their holdings by 2.2M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology